# ReCor Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/recor-medical

- Industry: Medical Devices & Equipment
- Headquarters: Palo Alto, US
- Website: www.recormedical.com
- Total disclosed funding: $15M
- Latest round: Series D (Apr 13, 2015)
- Investors on record: 2

## About

ReCor Medical, Inc. is a US-based company focused on developing innovative therapies for chronic care, particularly in treating hypertension. Their advanced technologies aim to improve patient outcomes through effective medical devices.Founded in 2009 and headquartered in Palo Alto, California, ReCor Medical specializes in medical device solutions for hypertension. The company is led by CEO Andy Weiss and was founded by Manohar Iyer. ReCor Medical has undergone strategic development since its inception, producing two significant funding rounds, with the latest being a Series D round in July 2018, where they raised USD 15.00 mn from lead investor Otsuka Pharmaceutical Co., Ltd. This funding supports their ongoing efforts to enhance hypertension treatment and expand their market presence globally.ReCor Medical specializes in innovative chronic care therapies with a focus on hypertension treatment. The company's flagship product, the PARADISE® Ultrasound Renal Denervation System, employs advanced ultrasound technology to deliver targeted renal denervation, aimed at reducing office systolic blood pressure (SBP) in patients with treatment-resistant hypertension. Clinical evidence from RADIANCE clinical trials indicates significant reductions in SBP, with reported decreases of -17.7 mmHg and -17.3 mmHg at 36 months for the RADIANCE-HTN SOLO and TRIO studies, respectively. The company serves a diverse clientele, including hospitals, healthcare providers, and patients suffering from hypertension across various geographical markets, including the United States and Europe, where the product is CE marked and FDA approved under specific indications.ReCor Medical's revenue model is structured around the sale of its medical devices, primarily the PARADISE® system, to healthcare institutions and providers. Transactions typically occur through direct sales to hospitals and clinics, where the company establishes partnerships to facilitate access to its products. These transactions are structured as direct-to-business sales, where healthcare entities purchase devices for patient treatment. Pricing plans for the PARADISE system are tailored to institutional buyers, reflecting the advanced technology and clinical efficacy of the product. The procurement process involves negotiations that consider the specific needs of the client and the competitive landscape of hypertension treatment solutions.In July 2018, ReCor Medical raised USD 15.00 mn in a Series D funding round led by Otsuka Holdings Co., Ltd. This investment aims to strengthen Otsuka's medical device business, advance hypertension treatment, and support the global commercialization of ReCor's PARADISE® system. The company plans to leverage this funding to enhance its product offerings and expand into new geographical markets, specifically targeting regions in Europe and Asia by 2023.

## Funding rounds

- Series D, Apr 13, 2015, $15M — Sofinnova Partners, Otsuka Pharmaceutical Co., Ltd.

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series D
- Otsuka Pharmaceutical Co., Ltd. — Series D